Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review.

ABSTRACT: Breast carcinoma is the most frequent and the second leading cause of cancer mortality in women worldwide. Current treatment decisions are based on tumor profiling of the initial tissue biopsy. Cancer though evolves both spatially and temporarily in a significant percentage of patients during treatment. However, sequential biopsies from the primary tumor or its metastatic sites are not either convenient or feasible in the majority of cases. In the era of precision medicine, analysis of circulating blood-based biomarkers in the field of liquid biopsies provides an insight into the dynamic molecular profiling of the primary tumor and its metastases, in a relatively non-invasive way. The latter permits not only patient stratification but also longitudinal evaluation of treatment response, whe

SUBMITTER: Fiste O 

PROVIDER: S-EPMC7791253 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature